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Considerable attention has been given to CCR6+ IL-17-secreting CD4+ T cells (Th17) in the pathology of a
number of autoimmune diseases including multiple sclerosis (MS). However, other Th subsets also play
important pathogenic roles, including those that secrete IFNc and GM-CSF. CCR6 expression by Th17 cells
allows their migration across the choroid plexus into the cerebrospinal fluid (CSF), where they are
involved in the early phase of experimental autoimmune encephalomyelitis (EAE), and in MS these cells
are elevated in the CSF during relapses and contain high frequencies of autoreactive cells. However, the
relatively low frequency of Th17 cells suggests they cannot by themselves account for the high percent-
age of CCR6+ cells in MS CSF. Here we identify the dominant CCR6+ T cell subsets in both the blood and
CSF as non-classic Th1 cells, including many that secrete GM-CSF, a key encephalitogenic cytokine. In
addition, we show that Th cells secreting GM-CSF but not IFNc or IL-17, a subset termed GM-CSF-
only-secreting Th cells, also accumulate in the CSF. Importantly, in MS the proportion of IFNc- and
GM-CSF-secreting T cells expressing CCR6 was significantly enriched in the CSF, and was elevated in
MS, suggesting these cells play a pathogenic role in this disease.
 2017 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
A number of biological therapies that target the immune system
have proved effective in reducing relapse rates in multiple sclerosis
(MS), an inflammatory demyelinating disease of the central ner-
vous system (CNS). However, identification and therefore specific
and effective therapeutic targeting of the relevant pathogenic T cell
subsets remains unresolved. Considerable attention has been given
in recent years to the role of CD4+ T helper (Th) 17 cells in the
pathogenesis of multiple sclerosis. In experimental autoimmune
encephalomyelitis (EAE) disease activity is reduced in the absence
of key Th17 pathway molecules including interleukin (IL) – 17A
itself, IL-23 that drives the preferential accumulation of Th17 cells,
and RORct – the transcription factor required for Th17 differentia-
tion (Rangachari and Kuchroo, 2013). Th17 cells are characterised
by the production of IL-17A, as well as a number of other cytokines
including IL-17F, IL-22 and IL-21, although some of these overlapwith other distinct Th subsets (Annunziato et al., 2012). The che-
mokine receptor CCR6 is expressed by virtually all Th17 cells, along
with the C-type lectin CD161 (NKR-P1A), and allows the cells to
cross endothelial barriers rich in CCL20. High expression of
CCL20 has been demonstrated in the choroid plexus, and in EAE
CCR6 expression is required for the initial wave of T cells entering
the CNS, with a later wave more dependent on CXCR3 (Liston et al.,
2009; Reboldi et al., 2009), a receptor predominantly associated
with Th1 cells that secrete IFNc without IL-17A.
Multiple lines of evidence suggest a role for Th17 in MS patho-
genesis, including an elevated frequency of Th17 cells in the CSF as
compared to the blood, increased Th17 frequencies in both blood
and CSF during relapses (Brucklacher-Waldert et al., 2009;
Durelli et al., 2009), and the detection of IL-17A+ T cells in brain
parenchyma from MS post-mortem tissue (Tzartos et al., 2008).
An additional population of T cells that co-express IFNc and IL-
17A, considered to be of a Th17 lineage, can also be found in both
the blood and brain in MS (Edwards et al., 2010; Kebir et al., 2009).
Although there has been a strong focus on IL-17A and IFNc produc-
tion by T cells in EAE and MS, surprisingly neither cytokine ispatho-
Table 1
Characteristics of patients for peripheral blood and matched CSF analysis.
MS group
Age* Gender (F:M) Disease duration
(months)
EDSS at
sampling
50.4 (31.1–65.5) 11:2 15 (3–276) 2.0 (0.0–6.0)
OND group
Age* Gender (F:M)
47.0 (32.0–52.5) 11:2
Diagnosis
Recurrent intermittent, neuropathic pain, small vessel disease (4), facial pain,
facial numbness, visual problems, fibromyalgia, headaches (2), idiopathic
intracranial hypertension (2)
* Median (range).
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to be the non-redundant cytokine required for EAE pathogenesis
(Codarri et al., 2011). GM-CSF is expressed by a number of T cells
subsets including Th1 and Th17, as well as a recently described
population that expressed GM-CSF in the absence of both IFNc
and IL-17, termed GM-CSF-only-secreting or single-positive GM-
CSF Th cells (Noster et al., 2014). Interestingly, GM-CSF secreting
B cells have also now been identified in MS (Li et al., 2015). As a
consequence, GM-CSF is currently a therapeutic target in a number
of autoimmune and inflammatory diseases, including MS
(Constantinescu et al., 2015).
Despite the prominent attention given to the role of Th17 cells
in MS, much of which of has been due to their relative dominance
over Th1 cells in EAE, the absolute frequencies of Th17 cells in the
blood and CSF, even during MS relapses, is very low. This contrasts
with the high frequency of CCR6+ CSF cells reported in both EAE
and MS (Reboldi et al., 2009). Interestingly, CCR6+ myelin-
reactive T cell clones derived from persons with MS produce a
range of cytokines, including IFNc, IL-17 and GM-CSF (Cao et al.,
2015). Potentially pathogenic CCR6+ Th subsets that do not secrete
IL-17A includes non-classic or non-conventional Th1 cells, a popu-
lation originally characterised by the expression of CD161 and/or
CCR6 (Acosta-Rodriguez et al., 2007; Becattini et al., 2015; Maggi
et al., 2010, 2012). Epigenetic analysis of these cells showed that
they most likely originate from Th17 cells, but have lost their abil-
ity to produce IL-17A (Mazzoni et al., 2015), with studies in juve-
nile idiopathic arthritis demonstrating their presence in both the
blood and synovial fluid. In this study we explored the association
of CCR6 with the pathogenic cytokines IL-17, IFNc and GM-CSF in
CD4+ T cells and in particular their association with MS. We
demonstrate that the dominant CSF CD4+ T cell subset is not com-
posed of IL-17-secreting T cells, but non-classic/non-conventional
Th1 cells as well as GM-CSF-only-secreting Th cells. These data
suggest a widening of the CD4+ T cell subsets implicated in MS
pathogenesis, with implications for their therapeutic targeting.2. Methods
2.1. Experimental design
Ethical approval for the study was provided by the Human
Biorepository Research Centre (University of Birmingham), North
West Research Ethics Committee (12/NW/0828) and West Mid-
lands Research Ethics Committee (11/WM/0206). All subjects pro-
vided written informed consent to participate in this study, in
accordance with the Declaration of Helsinki. Matched peripheral
blood and CSF samples were prospectively collected from persons
who underwent routine diagnostic lumbar puncture, were there-
fore not on disease-modifying therapies at the time of sampling,
and additionally had not received steroids for at least 3 months
prior to sampling. Blinding was achieved as all samples were anal-
ysed before the diagnosis had been formally determined. Ethical
approval for the study of peripheral blood from healthy volunteer
donors was provided by the Life and Health Sciences Ethical
Review Committee (University of Birmingham). Matched blood
and CSF samples were collected from persons with MS (n = 13) ful-
filling the diagnostic criteria according to the 2010 revisions of the
McDonald criteria (Polman et al., 2011), as well as an identical
number of age- and gender-matched other neurological disease
controls (OND) excluding any inflammatory OND (Table 1).2.2. Preparation of CSF and peripheral blood
CSF was obtained by non-traumatic lumbar puncture, collected
into polypropylene tubes, centrifuged (400g, 8 min), the super-Please cite this article in press as: Restorick, S.M., et al. CCR6+ Th cells in the cer
genic non-classic Th1 cells and GM-CSF-only-secreting Th cells. Brain Behav. Inatant removed and the cell pellet processed for culture and mar-
ker analysis as described below. anti-coagulated peripheral blood
samples (EDTA tubes) were diluted with an equal volume of
RPMI-1640 (Sigma-Aldrich), layered onto Ficoll-Paque Plus (GE
Healthcare Bioscience), and centrifuged at 400g, 20 C for 30 min.
The peripheral blood mononuclear cell (PBMC) layer was removed
and washed three times in RPMI-1640 before counting. All samples
were kept at room temperature and processed within 2 h of collec-
tion. The consistency of this approach ensures that variability is
kept to a minimum, and that any variation seen is equally present
in the MS and control cohorts. CSF sample volumes were 5–15 ml
(median 7.3 ml), yielding 400–17,000 cells (median 2750 cells).
2.3. Surface and intracellular marker analysis
Where indicated cells were re-suspended in RPMI-1640, 10%
heat-inactivated fetal calf serum (HIFCS; Sigma-Aldrich) and stim-
ulated with phorbol myristate acetate (PMA; 50 ng/ml), ionomycin
(750 ng/ml) and Brefeldin A (2 mg/ml) (all Sigma-Aldrich) for 3 h at
37 C, 5% CO2. This protocol has been widely used to reveal the
cytokine production capabilities of T cells, including studies on
MS (Mazzoni et al., 2015). Cells were incubated with antibodies
specific for surface markers for 20 min at 4 C before washing. To
detect CCR6, cells were stained at room temperature before and
after cell culture. Where required, cells were fixed and perme-
abilised according to the manufacturer’s instructions (FIX &
PERM, Life Technologies) before staining with antibodies specific
to intracellular markers. Cells were re-suspended in phosphate-
buffered saline (PBS) 2% bovine serum albumin (BSA) for flow cyto-
metric analysis, which was performed using a CyAnTM ADP flow
cytometer with data analysed using Kaluza Flow Cytometry Anal-
ysis Software (Beckman Coulter). Isotype control antibodies or
unstimulated controls (for cytokine analysis) were used to deter-
mine positivity.
2.4. CD4+ T cell positive isolation
PBMC were washed in filter-sterilized PBS, 2 mM EDTA
(ethylenediamine tetra-acetic acid), 0.5% BSA (MACS buffer; 4 C),
and re-suspended in 80 lL of MACS buffer with 20 lL of CD4+ T
Cell Microbeads (Miltenyi Biotech) per 107 total cells for 20 min
at 4 C, before washing in cold MACS buffer and being re-
suspended in 500 lL of MACS buffer. The cell suspension was
added to a pre-rinsed MS column on a Mini-MACS separator mag-
net (Miltenyi Biotech). The column was washed three times with
500 ll of cold MACS buffer then removed from the magnet and
the CD4+ fraction eluted with 1 ml MACS buffer and firm pressure
on the column from a plunger. CD4+ T cells isolated using this
method of positive selection have been shown to maintain func-
tional activity (Akdis et al., 1995).ebrospinal fluid of persons with multiple sclerosis are dominated by patho-
mmun. (2017), http://dx.doi.org/10.1016/j.bbi.2017.03.008
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CD4+ T cells were positively isolated from PBMC of healthy vol-
unteer donors as described above and re-suspended in RPMI 1640,
10% HIFCS at 2.67  106/ml. The chemokines, CCL20 and CXCL12
(Peprotech), were diluted to the desired concentration with RPMI
1640, 10% HIFCS, and 235 ll added to the bottom well of a 5 mm
96 well HTS Transwell permeable support (Sigma-Aldrich), allow-
ing equilibration at 37 C, 5% CO2 for 1 h. 75 ll of the cell suspen-
sion was slowly added to the top well and incubated at 37 C, 5%
CO2 for three hours. The bottom and top compartments were re-
suspended and transferred to separate tubes for stimulation with
PMA and ionomycin and analysis of cytokine production as
described above. AccuCheck counting beads (Thermo Fisher Scien-
tific) were included to determine cell migration.
2.6. Antibodies
All antibodies were used at the concentration recommended by
the manufacturer or pre-titrated for optimal staining. The follow-
ing antibodies were used in this study; anti-CD3 APC-eFluor 780
(UCHT1), -CD4 APC (OKT4), -CD161 PE-Cy7 (HP-3G10), -IFNc eFlu-
or450 or PE (45.B3), -IL-17A eFluor 488 (eBio64DEC17), -IL-22 PE
(22URT1), -IL-21 PE (eBio3A3-N2), -IL-17F PE (SHLR17), -T-bet PE
(eBio4B10), -RORct PE (AFKJS-9) (eBioscience), anti-CD3 Brilliant
Violet 510 (OKT 3), -CD4 PE-Cy7 (OKT4), -CD8 Brilliant Violet
510 (RPA-T8), -CD25 PerCP-Cy5.5 (BC96), -CCR6 PE or Alexa Fluor
(AF) 647 (G034E3), -CCR7 AF488 (G043H7), -CXCR3 AF647
(G025H7), anti-CD45RA PE-CF594 (HI100), -CD45RO PE-CF594
(UCHL1), -GM-CSF PE (BVD2-21C11) (BD Pharmingen), and anti-
CD4 PE-Vio770 (VIT 4) (Miltenyi Biotec).
2.7. CD4+CD25 T cell negative isolation
PBMC were washed in filter-sterilized PBS, 2 mM EDTA, 0.5%
BSA (MACS buffer; 4 C), and re-suspended in 90 lL of MACS buffer
with 10 lL of CD4+ T Cell Biotin-Antibody Cocktail (Miltenyi Bio-
tech) per 107 total cells for 5 min at 4 C. 20 lL of anti-biotin
Microbeads (Miltenyi Biotech) per 107 total cells was then added
for 10 min at 4 C, before increasing volume to 500 ml with MACS
buffer. The cell suspension was added to a pre-rinsed LD column
on a Midi-MACS separator magnet (Miltenyi Biotech). The column
was washed with 1 ml of cold MACS buffer and the collected cells
added to a second pre-rinsed LD column, this column was washed
three times with 1 ml of cold MACS buffer to collect the unlabelled
CD4+ fraction. CD4+ cells were washed and re-suspended in 90 lL
of MACS buffer with 10 lL of CD25 Microbeads (Miltenyi Biotech)
per 107 total cells for 15 min at 4 C, before washing in cold MACS
buffer and being re-suspended in 500 lL of MACS buffer. The cell
suspension was added to a pre-rinsed MS column on a Mini-
MACS separator magnet (Miltenyi Biotech), and the column was
washed three times with 500 ml of cold MACS buffer to collect
the unlabelled CD4+ CD25 cell fraction.
2.8. Purification of cytokine-secreting cells
CD4+CD25 T cells, isolated as above, were stimulated for 3 h
with PMA (50 ng/ml) and ionomycin (500 ng/ml) and cultured at
a density of 5  106 cells/cm2. Cells were collected from the plate
by washing with cold MACS buffer (4 C), and washed three times.
Cold MACS buffer (80 ll/107 cells) and each of the cytokine catch
reagents (10 ll/107 cells; Cytokine Secretion Assay-Cell Enrich-
ment and Detection Kit, Miltenyi Biotech) were added and incu-
bated at 4 C for 5 min. RPMI 1640, 10% HIFCS warmed to 37 C
was added to dilute the cells to 105/ml and incubated for 45 min
at 37 C, 5% CO2 spinning on a MACS Rotator (Miltenyi Biotech).Please cite this article in press as: Restorick, S.M., et al. CCR6+ Th cells in the cer
genic non-classic Th1 cells and GM-CSF-only-secreting Th cells. Brain Behav. ICells were kept at 4 C for 10 min then washed in cold MACS buffer,
centrifuged (300g, 10 min, 4 C) and re-suspended in cold buffer at
a concentration of 80 ll/107 cells with 10 ll/107 cells of each cyto-
kine detection antibody. Cells were incubated at 4 C for 10 min
and washed with cold MACS buffer, before further staining as
required. Cytokine positive cells were sorted using fluorescence
activated cell sorting (Mo-Flo, Beckman Coulter).
2.9. Gene expression analysis
RNA isolation and cDNA synthesis were performed using the
lMACS One-step cDNA Kit (Miltenyi Biotech) according to the
manufacturer’s instructions. Synthesized cDNA was eluted from
the column and collected with 50 ll cDNA Elution Buffer for quan-
titative real time PCR (qRT-PCR). Reactions were performed in
duplex, using GAPDH as the control gene, in a 384 well plate with
FastStart TaqMan Probe Master Mix (Roche). All reactions were
performed on a Light Cycler 480 (Roche) and analysed using the
Light Cycler 480 SW 1.5 software. The following TaqMan pri-
mer/probe sets were used (Life Technologies); GAPDH
Hs02758991_g1 (VIC), TBX21 Hs00203436_m1 (FAM), RORC
Hs01076122_m1 (FAM), IFNG Hs00989291_m1 (FAM), IL17A
Hs00174383_m1 (FAM). Relative gene expression (R) was analysed
as 2[ DCt sample  DCt control].
2.10. Data analysis
Data were analysed using GraphPad Prism 6 (GraphPad Soft-
ware Inc.). Statistical analysis used was as specified for each figure.
The D’Agostino & Pearson omnibus normality test was used to
determine if the datasets were normally distributed.
3. Results
3.1. The dominant CCR6+ Th subset in the CSF secretes IFNc and is
increased in MS
Although CCR6 is known to be expressed by a number of patho-
genic and regulatory CD4+ Th subsets (Comerford et al., 2010), the
high expression of CCR6 on CSF CD4+ T cells in MS has been previ-
ously attributed to IL-17-secreting Th17 cells without determina-
tion of the actual frequency of these cells (Reboldi et al., 2009).
Given that IL-17-secreting CD4+ T cells have been reported at rela-
tively low frequencies in the blood and CSF, even in MS
(Brucklacher-Waldert et al., 2009; Durelli et al., 2009), we there-
fore examined the expression of both IL-17A and IFNc in relation
to the expression of CCR6. As expected all IL-17A-secreting CD4+
memory Th cells expressed CCR6 (Fig. 1A,B) and were present at
a low frequency, consistent with previous reports in MS
(Brucklacher-Waldert et al., 2009; Durelli et al., 2009). Consistent
with their potential involvement in the pathogenesis of MS, the
relative frequency of IL-17A+ CD4+ memory T cells in the CSF was
consistently and significantly increased in MS but not OND
(Fig. 1D), as well as their absolute number (Fig. 1G) as previously
described (Brucklacher-Waldert et al., 2009; Durelli et al., 2009),
although even in persons with MS they constituted only a small
percentage of the total cells in the blood and CSF. In contrast there
were much larger populations of CCR6+ CD4+ memory T cells that
secreted IFNc. The percentage of IFNc+ cells that expressed CCR6
was significantly enriched within CSF as compared to the periph-
eral blood, although this enrichment was observed for both MS
and OND cohorts (Fig. 1C); these cells represented approximately
50% of the CSF IFNc-secreting population. CCR6+ IFNc+ CD4+ mem-
ory T cells were significantly enriched in the CSF in both MS and
OND, both for percentage and absolute numbers (Fig. 1E,H). Similar
changes were also observed for the CCR6-IFNc+ CD4+ memory Tebrospinal fluid of persons with multiple sclerosis are dominated by patho-
mmun. (2017), http://dx.doi.org/10.1016/j.bbi.2017.03.008
Fig. 1. CCR6+ CD4+ Th cells in the cerebrospinal fluid predominantly secrete IFNc, not IL-17A, and are elevated in MS. A. Representative data demonstrating CCR6 expression
on IL-17+ and IFNc+ cells (gated on CD3+CD45RO+CD8 cells) in PBMC and matched CSF cells. Numbers represent the percentage of cells within the quadrant, with negative
gates set based on an un-stimulated controls. B, C. The percentage of CCR6+ CD4+ T cells that expresses either IL-17A (B) or IFNc (C) in PBMC and matched CSF. D-F. The
percentage of CD4+ memory T cells of a CCR6+IL-17A+ (D), CCR6+IFNc+ (E) or CCR6IFNc+ phenotype (F). G-I. The absolute number of CCR6+IL-17A+ (G), CCR6+IFNc+ (H) or
CCR6IFNc+ (I) CSF CD4+ memory T cells. Box and whiskers plots are shown with minimum and maximum values. Wilcoxon matched-pairs signed rank (B-F) and Mann-
Whitney tests (G–I) (* = p < 0.05, ** = p < 0.01, *** = p < 0.001); all other comparisons were non-significant (p > 0.05).
4 S.M. Restorick et al. / Brain, Behavior, and Immunity xxx (2017) xxx–xxxcells, although the increase in the OND CSF was far less consistent
and not statistically significant (Fig. 1F,I).
The above data demonstrate that the previously reported
increase of CCR6+ CD4+ memory T cells in the CSF (Reboldi et al.,
2009) can be largely attributed to IFNc-secreting, rather than IL-
17A-secreting, T cells, and that these cells are increased in MS
CSF as compared to OND. The characterisation of CCR6+ IFNc
CD4+ Th cells has been previously reported by a number of differ-
ent groups, and they are referred to as non-classic Th1, ex-Th17 or
non-conventional Th1 cells (Annunziato et al., 2014; Maggi et al.,
2010; Maggi et al., 2012, 2015). Consistent with the reported phe-
notype and potential origin of these cells we confirmed that, in our
studies, cells that express CCR6 in combination with IFNc, but
which do not express IL-17A, expressed a combination of transcrip-
tion factors that are associated with Th1 and Th17 subsets (Fig. S1).Please cite this article in press as: Restorick, S.M., et al. CCR6+ Th cells in the cer
genic non-classic Th1 cells and GM-CSF-only-secreting Th cells. Brain Behav. I3.2. CCR6 expressed on IFNc-secreting CD4+ memory T cells is
functional
Although CCR6 was clearly expressed on a subset of IFNc-
secreting CD4+ memory T cells, consistent with a number of pub-
lished studies, it has yet to be established whether the receptor
is functional, especially given the significantly reduced intensity
of CCR6 expression observed on these cells (Fig. 2A-B). Migration
assays using purified CD4+ T cells demonstrated that both IL-
17A+IFNc and IFNc+IL-17A T cells migrated towards CCL20 in a
dose-dependent manner, as well as responding to the control che-
mokine CXCL12 which acts through CXCR4 found uniformly on all
subsets (Fig. 2D-E). The response to CCL20 for the IFNc-secreting T
cells appeared to be lower than for the Th17 cells (Fig. 2D), consis-
tent with the observed reduction in median fluorescence intensityebrospinal fluid of persons with multiple sclerosis are dominated by patho-
mmun. (2017), http://dx.doi.org/10.1016/j.bbi.2017.03.008
Fig. 2. CCR6 expressed on IFNc+IL-17A CD4+ memory T cells is functional. A. Expression of CXCR3 and CCR6 gated on CD4+CD45RO+ memory T cells. B, C. Median
fluorescence intensity (MFI) of CCR6 (B) and CXCR3 (C) in CD4+CD45RO+ memory T cells expressing combinations of CCR6, IFNc and IL-17A. Repeated measures ANOVA with
Bonferroni’s multiple comparison test (n = 5); * = p < 0.05, ** = p < 0.01, *** = p < 0.001. All other comparisons were non-significant (p > 0.05). D, E. Purified CD4+ T cells were
migrated in a transwell in response to the indicated concentrations of CCL20 (D) or CXCL12 (E). The migrated and non-migrated fractions were then stimulated with PMA and
ionomycin before determining IFNc and IL-17 expression, allowing calculation of the migration of each subset. Data represent the mean and SEM of three independent
experiments.
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migrate in response to CXCL12 (Fig. 2E).
3.3. GM-CSF-secreting Th cells are elevated in MS
Collectively, our data suggest that CCR6+ IFNc-secreting CD4+ T
cells have both the chemokine receptor expression and cytokine
secretion capabilities that would allow them to both enter the
CNS, at least at the level of the choroid plexus, and mediate either
immune surveillance functions, or if autoreactive, a pathogenic
role.
The presence of CCR6 on a subset of IFNc-secreting CD4+ T cells,
with absent IL-17A production, indicates that this subset shares
features of both Th17 and Th1 cells, as reported in a number of
studies (Maggi et al., 2010, 2012). We confirmed the absence of a
number of Th17-associated cytokines, IL-17F, IL-21 and IL-22
within the CCR6+ IFNc+ subset, despite them being produced by
both IL-17+ and IL-17+IFNc+ CCR6+ subsets (Fig. S2A). As part of this
analysis we also examined the expression of GM-CSF, and con-
firmed its broad expression (Fig. S2B-C).
Because GM-CSF is thought to be a key encephalitogenic cyto-
kine, being non-redundant in EAE, we evaluated its expression in
both IL-17A- and IFNc-secreting cells, as well as those cells that
secrete neither of these cytokines, previously referred to as GM-
CSF-only-secreting or GM-CSF single positive Th cells (Herndler-
Brandstetter and Flavell, 2014; Noster et al., 2014; Sheng et al.,Please cite this article in press as: Restorick, S.M., et al. CCR6+ Th cells in the cer
genic non-classic Th1 cells and GM-CSF-only-secreting Th cells. Brain Behav. I2014). In a cohort of persons with MS, the frequency of GM-CSF+
CD4+ memory T cells was significantly increased in the CSF as com-
pared to the blood, with a lower and non-significant increase in the
OND cohort (Fig. 3A,B). Although these data are consistent with
previously reported data (Noster et al., 2014), we failed to demon-
strate a significant difference between the CSF of MS and OND
cohorts when measuring the frequency of these cells (p = 0.079),
although there was a significant increase in their numbers
(Fig. 3C). There was also clear evidence that some individuals in
the OND cohort had high frequencies of GM-CSF+ CD4+ memory
T cells in their CSF (Fig. 3B).
We next determined which Th subsets were contributing to the
elevations in GM-CSF+ CD4+ memory T cells in the CSF of persons
with MS. CCR6+IL-17+ CD4+ T cells in both OND and MS cohorts,
and in both the blood and CSF, were capable of secreting GM-CSF
to similar degrees (Fig. 4A). By contrast the frequencies of CCR6+-
IFNc+ cells that can produce GM-CSF were significantly elevated
in the CSF, as compared to the blood, although this was equally ele-
vated in the OND and MS cohorts (Fig. 4B). A similar pattern was
also observed for CCR6IFNc+ CD4+ T cells (Fig. 4C). When consid-
ering the numbers of these cells, there were significant increases
for all GM-CSF-secreting populations of CSF CD4+ T cells in MS,
as compared to OND (Fig. 4F–H). However, differences were
observed when considering the IL-17IFNc CD4+ T cells that
express GM-CSF. This population has previously been identified
and referred to as GM-CSF-only-secreting (Herndler-Brandstetterebrospinal fluid of persons with multiple sclerosis are dominated by patho-
mmun. (2017), http://dx.doi.org/10.1016/j.bbi.2017.03.008
Fig. 3. CCR6+IFNc+ CD4+ memory T cells in the CSF secrete GM-CSF and are elevated in MS. Matched PBMC and CSF cells were stimulated with PMA and ionomycin and
stained for surface CCR6, and intracellular IFNc, IL-17 and GM-CSF. Representative data is shown from a person with MS (A). All samples were gated on CD3+CD4+CD45RO+
memory T cells. Box and whiskers plots are shown with minimum and maximum values. Wilcoxon matched-pairs signed rank test (B,C); * = p < 0.05, ** = p < 0.01. All other
comparisons were non-significant (p > 0.05).
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persons with MS for the CCR6+IL-17IFNcGM-CSF+ CD4+ T cell
subset, both for percentage and frequency (Fig. 4D), as well as for
the equivalent CCR6 population (Fig. 4E), although again elevated
in absolute numbers in both cohorts (Fig. 4I-J). These data demon-
strate that there are increases in GM-CSF secreting T cells in the
CSF of persons with MS, but that this increase is largely confined
to CD4+ T cells that do not express either IFNc or IL-17.
Overall, these data suggest that there is a selective recruitment
of CCR6+ IFNc-secreting CD4+ memory T cells to the CSF that is
increased in MS, that these cells are able to produce the encephal-
itogenic cytokine GM-CSF, and that these cells constitute the dom-
inant CCR6+ CD4+ Th subset in the CSF in MS.
4. Discussion
There is a large body of literature implicating CD4+ Th17 cells in
the pathogenesis of MS (Brucklacher-Waldert et al., 2009; Cao
et al., 2015; Durelli et al., 2009; Kebir et al., 2009; Li et al., 2011;
Tzartos et al., 2008). These data include the role of these cells in
EAE, where they have been shown to enhance disease by driving
the first phase of recruitment across the choroid plexus barrier
(Liston et al., 2009; Reboldi et al., 2009). In MS, Th17 cells are
increased in the CSF and peripheral blood during relapses
(Brucklacher-Waldert et al., 2009; Durelli et al., 2009), and are pre-
sent in in parenchymal post-mortem tissue (Tzartos et al., 2008).
CCR6 is a well validated marker expressed on virtually all Th17
cells, and myelin/MOG-specific T cells are found within the
CCR6+ subset (Cao et al., 2015; Sallusto et al., 2012). Consequently,
some studies have relied on the expression of CCR6 to indicate the
presence of Th17 cells. In particular the frequency of CCR6+ T cells
in MS CSF was suggested to indicate the dominance of Th17 cells
(Reboldi et al., 2009). However, it is now clear that CCR6 is not
restricted to Th17 cells, but can include both regulatory cells and
other potentially pathogenic subsets including IFNc- and GM-
CSF-secreting CD4+ T cells. In this study we have determined that
the dominant CCR6+ CD4+ T cell subset in MS is not the Th17 subset
but either non-classic Th1 cells that secrete IFNc and GM-CSF, or
GM-CSF-only-secreting CD4+ Th cells.
A number of studies have characterised a population of Th1
cells termed non-classic or non-conventional, that express many
markers associated with Th17 cells, but importantly do not pro-Please cite this article in press as: Restorick, S.M., et al. CCR6+ Th cells in the cer
genic non-classic Th1 cells and GM-CSF-only-secreting Th cells. Brain Behav. Iduce IL-17A (Annunziato et al., 2014; Maggi et al., 2014; Maggi
et al., 2010, 2012), and our own data were consistent with the pub-
lished literature (Figs. 1, S1,S2). These cells are likely to have been
derived from Th17 cells, as the IL-17A locus remains partially de-
methylated and they share many transcriptional features of Th17
cells (Annunziato et al., 2014; Becattini et al., 2015; Mazzoni
et al., 2015). The origin of these cells is consistent with studies in
mice where fate-mapping of Th17 cells revealed their ability to dif-
ferentiate to a Th1 phenotype, and interestingly this was particular
prevalent in EAE (Hirota et al., 2011). The presence of high num-
bers of CCR6+ Th1 cells in the CSF reveals their ability to efficiently
migrate across the choroid plexus. The ligand for CCR6, CCL20, has
been previously found at high levels in the choroid plexus suggest-
ing that CCR6 itself is involved in their migration (Reboldi et al.,
2009). Although we observed a reduced expression of CCR6 on
IFNc-secreting as compared to IL-17A-secreting CD4+ memory T
cells, we were able to demonstrate that this receptor is functional,
suggesting that CCR6 may participate in their migration across
through the choroid plexus. It is likely that CXCR3 also participates
in this migration process, as non-classic Th1 cells also express
CXCR3 (Maggi et al., 2012) and virtually all cells arriving in the
CSF are CXCR3+ (Kivisakk et al., 2002).
The two-step model proposed based on data from EAE models
suggests that Th17, or at least CCR6+ cells, are required for the first
phase of disease being recruited across the choroid plexus and/or
meninges (Reboldi et al., 2009). Once a few pathogenic T cells have
migrated through into the CNS and been re-activated by antigen
this would then drive activation of the parenchymal endothelial
barrier, reducing barrier integrity, and allowing a larger influx of
Th1 cells to enter during a second phase of disease; this scenario
might therefore suggest that CCR6+ Th1 cells are involved early
in the disease process. An alternative hypothesis can be suggested
based on data using a human TCR transgenic mouse that develops
spontaneous disease. In this model Th1 cells are involved earlier in
disease and then Th17 cells at a later stage when the tissue
becomes significantly affected (Lowther et al., 2013). We do not
have longitudinal data available in MS, but a much larger study
comparing different stages of MS may shed some light on when
non-classic Th1 cells are acting. It will also be of interest to deter-
mine if there is any prognostic relevance to their frequencies
within the CSF. Although we have demonstrated a high frequency
of CCR6+ Th1 cells in the CSF of persons with MS, there were alsoebrospinal fluid of persons with multiple sclerosis are dominated by patho-
mmun. (2017), http://dx.doi.org/10.1016/j.bbi.2017.03.008
Fig. 4. CCR6+ CD4+ GM-CSF-only-secreting T cells are elevated in MS. The percentage (A–E) of CD4+ memory T cells expressing the indicated combinations of CCR6, IL-17A,
IFNc and GM-CSF in PBMC and matched CSF. The absolute numbers of CSF CD4+ memory T cells of each phenotype are shown in F-J. Box and whisker plots are shown with
minimum and maximum values for each cohort. Wilcoxon matched-pairs signed rank (A-E) and Mann-Whitney tests (B–J) (* = p < 0.05, ** = p < 0.01); all other comparisons
were non-significant (p > 0.05).
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logical diseases. It is therefore likely that these cells are also
recruited in the absence of inflammation to provide an immune
surveillance role, with frequencies then increasing during episodes
of inflammation. Although none of the MS or control cohort were
on any immunomodulatory treatment at the time of sampling or
during the preceding 3 months, we cannot exclude a possible influ-
ence of any historical treatments. It would be interesting in future
studies, particularly in MS, to examine the impact of distinct
immunomodulatory treatments.
Although both IFNc-secreting Th1 and IL-17A-secreting Th17
cells infiltrate the CNS in MS and EAE, neither cytokine is abso-
lutely required for the induction of EAE. The ultimate pathogenicity
of CD4+ T cells is thought instead to relate to the production of GM-
CSF (Codarri et al., 2011). GM-CSF can be associated with either
Th1 or Th17 cells, including non-classic Th1 cells (Piper et al.,
2014), as well as a more recently described population of STAT5
regulated GM-CSF-only-producing Th cells (Herndler-
Brandstetter and Flavell, 2014; Noster et al., 2014; Piper et al.,
2014; Sheng et al., 2014). Elevations of GM-CSF secreting T cells
were previously observed in MS CSF (Noster et al., 2014), but this
was not attributed to a distinct Th subset. Our data demonstrate
that the dominant GM-CSF-secreting Th subsets are non-classic
Th1 cells and GM-CSF-only-secreting Th cells, being elevated in
the CSF as compared to the blood, and with elevated levels in MS
as compared to disease controls. There are of course some limita-
tions to our study. Further studies would be required to determine
the influence of disease duration, treatment regimens and impact
of relapse, in larger cohorts. Additionally, the analysis of CSF,
although clearly reflecting activity within CNS tissues may not
fully parallel populations observed in the tissue.
5. Conclusions
Our data have important implications not only for our under-
standing of the pathogenesis of MS, but also for therapeutic strate-
gies. Dramatic reductions in relapse rates have been achieved by
preventing T cell infiltration into the CNS, and there is emerging
evidence that targeting IL-17A might have some efficacy in MS
(Havrdova et al., 2016). The close transcriptional associations
between Th17 and non-classic Th1 cells might suggest that
approaches targeting shared pathways in these cells might also
be of benefit. For example, it is possible that RORct antagonists
may not only impact Th17 cells (Isono et al., 2014) but also the
non-classic Th1 lineage, and thereby impact on the pathogenic
autoreactive T cells contained within the CCR6+ T cell subset (both
Th17 and non-classic Th1). Even if RORct antagonists only impact
on Th17 cells, with chronic therapy, over time there may be an
impact on the conversion of Th17 cells to non-classic Th1 cells.
Further investigations will be required to determine the relative
impact of all Th17 pathway modulators on Th17 and CCR6+ Th1
cells, as well as the potential of targeting GM-CSF (Wicks and
Roberts, 2016).
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